more

ProNAi Therapeutics, Inc. (SRRA)

(Delayed Data from NSDQ)

$1.44 USD

+0.03 (2.13%)

Updated May 3, 2019 04:13 PM ET

After-Market: $1.44 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	23.68%
2	Buy	17.55%
3	Hold	9.21%
4	Sell	4.93%
5	Strong Sell	2.36%
S&P	500	10.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

Industry: NA

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

GSK Receives Regulatory Nod for Consumer Healthcare Demerger

by Zacks Equity Research Published on June 02,2022

GSK progresses with the separation of its Consumer Healthcare business from biopharmaceuticals into a separate public company, Haleon, as it gets regulatory approval from the FCA.

pharmaceuticals

Biotech Stock Roundup: SRRA Surges on GSK Buyout, HALO Offers Update & More

by Zacks Equity Research Published on April 14,2022

Acquisition news from GlaxoSmithKline (GSK) and HALO are a few key highlights from the biotech sector during the past week.

Glaxo (GSK) to Buy Sierra for $1.9B, Add Hematology Drug

by Zacks Equity Research Published on April 13,2022

The acquisition of Sierra Oncology (SRRA) will add late-stage oncology pipeline candidate, momelotinib to Glaxo's (GSK) hematology pipeline.

pharmaceuticals

RedHill's (RDHL) RHB-204 Gets FDA Fast Track Designation

by Zacks Equity Research Published on January 07,2021

RedHill (RDHL) gets Fast Track status from the FDA for the treatment of nontuberculous mycobacteria (NTM) disease.

pharmaceuticals

Altimmune (ALT) Begins Phase II Study for Chronic Hepatitis B

by Zacks Equity Research Published on December 31,2020

Altimmune (ALT) enrolls the first patient in a phase II study evaluating HepTcell for the treatment of patients with chronic hepatitis B. Shares rise.

medical

Nektar (NKTR) Begins Dosing in NKTR-255 Study for Two Cancers

by Zacks Equity Research Published on December 16,2020

Nektar (NKTR) doses the first patient in a phase I/II study on NKTR-255 in combination with Erbitux for treating head and neck squamous cell carcinoma or colorectal cancer. Shares up.

medical

Sierra Oncology, Inc (SRRA) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research Published on June 18,2020

Sierra Oncology, Inc (SRRA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).